Neurocognitive assessment in the clinical antipsychotic trials of intervention effectiveness (CATIE) project schizophrenia trial: Development, methodology, and rationale

Richard S E Keefe, Richard C. Mohs, Robert M. Bilder, Philip D. Harvey, Michael F. Green, Herbert Y. Meltzer, James M. Gold, Mary Sano

Research output: Contribution to journalReview article

90 Citations (Scopus)

Abstract

Patients with schizophrenia are severely impaired in crucial aspects of neurocognitive function. This impairment is the strongest clinical correlate of poor long-term outcome and adaptive dysfunction. Reports of neurocognitive enhancement with second generation antipsychotic medications have thus offered promise for improvement in the long-term outcome of patients with schizophrenia. However, the majority of these studies have had serious weaknesses in methodology, such as open-label design, small samples, or inappropriate dosing of medications. More recent studies have addressed these methodological issues but have been of short duration and have largely been sponsored by pharmaceutical companies. The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project is a unique opportunity to address the comparative neurocognitive effectiveness of available antipsychotic medications. This article describes the neurocognitive methods used in the schizophrenia trial of the CATIE project, including the selection and training of neurocognitive raters, patient inclusion criteria for assessment, rationale for the choice of neurocognitive instruments, and methodology for each neurocognitive test.

Original languageEnglish (US)
Pages (from-to)45-55
Number of pages11
JournalSchizophrenia bulletin
Volume29
Issue number1
DOIs
StatePublished - Jan 1 2003

Fingerprint

Antipsychotic Agents
Schizophrenia
Clinical Trials
Pharmaceutical Preparations

Keywords

  • Antipsychotic medications
  • Clinical trials
  • Cognition
  • Neurocognitive function
  • Neuropsychology
  • Schizophrenia

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Keefe, Richard S E ; Mohs, Richard C. ; Bilder, Robert M. ; Harvey, Philip D. ; Green, Michael F. ; Meltzer, Herbert Y. ; Gold, James M. ; Sano, Mary. / Neurocognitive assessment in the clinical antipsychotic trials of intervention effectiveness (CATIE) project schizophrenia trial : Development, methodology, and rationale. In: Schizophrenia bulletin. 2003 ; Vol. 29, No. 1. pp. 45-55.
@article{50d546e22c244f7fae36fd8a7c324252,
title = "Neurocognitive assessment in the clinical antipsychotic trials of intervention effectiveness (CATIE) project schizophrenia trial: Development, methodology, and rationale",
abstract = "Patients with schizophrenia are severely impaired in crucial aspects of neurocognitive function. This impairment is the strongest clinical correlate of poor long-term outcome and adaptive dysfunction. Reports of neurocognitive enhancement with second generation antipsychotic medications have thus offered promise for improvement in the long-term outcome of patients with schizophrenia. However, the majority of these studies have had serious weaknesses in methodology, such as open-label design, small samples, or inappropriate dosing of medications. More recent studies have addressed these methodological issues but have been of short duration and have largely been sponsored by pharmaceutical companies. The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project is a unique opportunity to address the comparative neurocognitive effectiveness of available antipsychotic medications. This article describes the neurocognitive methods used in the schizophrenia trial of the CATIE project, including the selection and training of neurocognitive raters, patient inclusion criteria for assessment, rationale for the choice of neurocognitive instruments, and methodology for each neurocognitive test.",
keywords = "Antipsychotic medications, Clinical trials, Cognition, Neurocognitive function, Neuropsychology, Schizophrenia",
author = "Keefe, {Richard S E} and Mohs, {Richard C.} and Bilder, {Robert M.} and Harvey, {Philip D.} and Green, {Michael F.} and Meltzer, {Herbert Y.} and Gold, {James M.} and Mary Sano",
year = "2003",
month = "1",
day = "1",
doi = "10.1093/oxfordjournals.schbul.a006990",
language = "English (US)",
volume = "29",
pages = "45--55",
journal = "Schizophrenia Bulletin",
issn = "0586-7614",
publisher = "Oxford University Press",
number = "1",

}

Neurocognitive assessment in the clinical antipsychotic trials of intervention effectiveness (CATIE) project schizophrenia trial : Development, methodology, and rationale. / Keefe, Richard S E; Mohs, Richard C.; Bilder, Robert M.; Harvey, Philip D.; Green, Michael F.; Meltzer, Herbert Y.; Gold, James M.; Sano, Mary.

In: Schizophrenia bulletin, Vol. 29, No. 1, 01.01.2003, p. 45-55.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Neurocognitive assessment in the clinical antipsychotic trials of intervention effectiveness (CATIE) project schizophrenia trial

T2 - Development, methodology, and rationale

AU - Keefe, Richard S E

AU - Mohs, Richard C.

AU - Bilder, Robert M.

AU - Harvey, Philip D.

AU - Green, Michael F.

AU - Meltzer, Herbert Y.

AU - Gold, James M.

AU - Sano, Mary

PY - 2003/1/1

Y1 - 2003/1/1

N2 - Patients with schizophrenia are severely impaired in crucial aspects of neurocognitive function. This impairment is the strongest clinical correlate of poor long-term outcome and adaptive dysfunction. Reports of neurocognitive enhancement with second generation antipsychotic medications have thus offered promise for improvement in the long-term outcome of patients with schizophrenia. However, the majority of these studies have had serious weaknesses in methodology, such as open-label design, small samples, or inappropriate dosing of medications. More recent studies have addressed these methodological issues but have been of short duration and have largely been sponsored by pharmaceutical companies. The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project is a unique opportunity to address the comparative neurocognitive effectiveness of available antipsychotic medications. This article describes the neurocognitive methods used in the schizophrenia trial of the CATIE project, including the selection and training of neurocognitive raters, patient inclusion criteria for assessment, rationale for the choice of neurocognitive instruments, and methodology for each neurocognitive test.

AB - Patients with schizophrenia are severely impaired in crucial aspects of neurocognitive function. This impairment is the strongest clinical correlate of poor long-term outcome and adaptive dysfunction. Reports of neurocognitive enhancement with second generation antipsychotic medications have thus offered promise for improvement in the long-term outcome of patients with schizophrenia. However, the majority of these studies have had serious weaknesses in methodology, such as open-label design, small samples, or inappropriate dosing of medications. More recent studies have addressed these methodological issues but have been of short duration and have largely been sponsored by pharmaceutical companies. The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project is a unique opportunity to address the comparative neurocognitive effectiveness of available antipsychotic medications. This article describes the neurocognitive methods used in the schizophrenia trial of the CATIE project, including the selection and training of neurocognitive raters, patient inclusion criteria for assessment, rationale for the choice of neurocognitive instruments, and methodology for each neurocognitive test.

KW - Antipsychotic medications

KW - Clinical trials

KW - Cognition

KW - Neurocognitive function

KW - Neuropsychology

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=0038148696&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038148696&partnerID=8YFLogxK

U2 - 10.1093/oxfordjournals.schbul.a006990

DO - 10.1093/oxfordjournals.schbul.a006990

M3 - Review article

C2 - 12908660

AN - SCOPUS:0038148696

VL - 29

SP - 45

EP - 55

JO - Schizophrenia Bulletin

JF - Schizophrenia Bulletin

SN - 0586-7614

IS - 1

ER -